OSWALDO CASTANEDA and M. GOPAL NAIR
Objective. To investigate the clinical efficacy, safety, tolerability, and toxicity profile of a metabolically stable antifolate, CH-1504, compared to methotrexate (MTX) in the treatment of rheumatoid arthritis (RA).
Methods. A 24-week open-label trial of MTX and CH-1504 was performed in 20 patients with RA.
Results. Improvements in clinical and laboratory indicators were observed in both study groups. Improvement in the CH-1504 group was greater than in the MTX group. Both treatments were generally well tolerated; however, the liver function test abnormalities and gastrointestinal related adverse events expected with this class of medication were not seen with CH-1504.
Conclusion. CH-1504 appears to be clinically efficacious and may possess a superior safety and tolerance profile compared to MTX. (J Rheumatol 2006;33:862-4)
Key Indexing Terms:
From the Universidad Peruana Cayetano Heredia, Lima, Peru; and College of Medicine, University of South Alabama, Mobile, Alabama, USA.
Supported in part by grant CA-27101 from the National Institutes of Health.
O. Castaneda, MD, PhD, Professor and Chair, Departments of Immunology and Rheumatology, Universidad Peruana Cayetano Heredia; M.G. Nair, PhD, Professor, College of Medicine, University of South Alabama.
Address reprint requests to Dr. M.G. Nair, College of Medicine, University of South Alabama, Mobile, AB 36688. E-mail: email@example.com
Accepted for publication December 29, 2005.